Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer
- 23 September 2009
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 26 (11) , 2486-2494
- https://doi.org/10.1007/s11095-009-9964-5
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2British Journal of Pharmacology, 2008
- LDL Receptor-Related Protein 1: Unique Tissue-Specific Functions Revealed by Selective Gene Knockout StudiesPhysiological Reviews, 2008
- Subtypes of Breast Cancer Show Preferential Site of RelapseCancer Research, 2008
- Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2008
- Capecitabine Therapy of Central Nervous System Metastases from Breast CancerJournal of Neuro-Oncology, 2007
- Brain Metastases: The HER2 ParadigmClinical Cancer Research, 2007
- Strategies to Improve Drug Delivery Across the Blood-Brain BarrierClinical Pharmacokinetics, 2007
- Breast Cancer Metastasis to the Central Nervous SystemThe American Journal of Pathology, 2005
- Blood-Brain Barrier Transport of Circulating Alzheimer′s Amyloid βBiochemical and Biophysical Research Communications, 1993
- Phenylalanine Transport Across the Blood‐Brain Barrier as Studied with the In Situ Brain Perfusion TechniqueJournal of Neurochemistry, 1987